This clinical trial is focused on studying neuroblastoma, a type of cancer that most often affects children and develops from immature nerve cells. The study will compare two different imaging methods used to detect this disease. The first method uses a substance called [18F]meta-fluorobenzylguanidine (also known as [18F]mFBG) in a type of scan called PET-CT. The second method uses iodine (123I) iobenguane (also known as [123I]mIBG) in a scan called SPECT-CT. Both substances are injected into the body and help to highlight areas where the cancer might be present.

The purpose of this study is to compare how well these two imaging methods can detect cancer in the bones of patients with neuroblastoma. Participants in the study will undergo both types of scans, and the results will be compared to see which method is more effective at finding cancerous lesions. The study will also look at other factors, such as the amount of radiation absorbed by the body during each type of scan and the number of cancerous areas detected.

This study is expected to take place over several years, with the goal of improving the way neuroblastoma is diagnosed and monitored. By comparing these two imaging methods, researchers hope to find the most accurate and safe way to detect this type of cancer, which could lead to better treatment outcomes for patients in the future.